Novartis Evaluating Submission Strategy for Painkiller Prexige in Various Countries Except US
August 12, 2009
Novartis Evaluating Submission Strategy for Painkiller Prexige in Various Countries Except US
Despite a report that Novartis intends to resubmit its application for the painkiller Prexige to the US Food and Drug Administration with a companion genetic test, the Swiss drugmaker says it is not trying to relaunch the drug in the US market.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Novartis Using PGx to Resuscitate Previously Failed Pain Drug Prexige with Companion Dx
August 5, 2009 / Pharmacogenomics Reporter - Novartis Eyeing US Market for Prexige Launch with Companion Test
February 10, 2010 / Pharmacogenomics Reporter - Qiagen Submits EGFR Companion Dx to FDA
January 15, 2013 / GenomeWeb Daily News - European Regulators Grant Conditional Approval for Pfizer's Xalkori; Abbott Begins Marketing ALK CDx
October 24, 2012 / Pharmacogenomics Reporter - Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter